4 Minute Read
Whether manufacturers are entering new therapeutic categories, exploring new indications for a current product, or looking to acquire a new product through acquisition, managing Gross-To-Net can be complex.
5 Minute Read
Updates on two significant regulatory topics, including the FDA decision on orphan-drug exclusivity regulations and highlights from the Kaiser Family Foundation 2022 Employer Benefits Survey.
5 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
6 Minute Read
Updates on four significant regulatory topics, including the inflation reduction act impact on research and development, Office of Inspector General studies on Average Sales Price, and a shift of...
3 Minute Read
Insights into specialty lite challenges and a new channel strategy that has emerged to help manufacturers balance patient access with their gross-to-net.
5 Minute Read
Updates on two significant regulatory topics, including value-based purchasing, interchangeabilty with biosimilars, and an end of 2022 roundup.
3 Minute Read
This is the first in a two-part blog series covering the ever-changing requirements by states as well as 2022 trends in Pricing Transparency Reporting.
5 Minute Read
Co-Founder and Chief Operating Officer Josh Halpern reviews key industry trends impacting product commercialization and access, including the shift to true data-driven commercialization, highlighted at the Access Insights Conference...
5 Minute Read
Regulatory and legal updates on three significant regulatory topics, including consumer price index, pricing transparency updates, and the impact of digital pharmacies.